v3.26.1
Segment Reporting - Summary of Segment Profit or Loss, Including Significant Expenses (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenues [Abstract]            
Total revenue $ 20,874   $ 15,288   $ 39,139 $ 29,396
Cost of product sales $ 243       $ 505  
Cost, Product and Service [Extensible Enumeration] Product [Member]   Product [Member]   Product [Member] Product [Member]
Research and development expense $ 61,891   $ 62,785   $ 127,154 $ 118,758
Share-based compensation expense 8,209   6,949   16,625 14,791
Total operating expenses 93,884   87,954   190,964 166,762
Other income (expenses):            
Interest and other income, net 5,033   6,935   10,859 14,814
Interest expense (345)   (391)   (681) (773)
Income tax expense (5)       (13) (226)
Net Loss (68,327) $ (73,333) (66,122) $ (57,429) (141,660) (123,551)
Product [Member]            
Revenues [Abstract]            
Total revenue 9,122       14,888  
Operating Segments            
Revenues [Abstract]            
Cost of product sales $ 243   $ 0   $ 505 $ 0
Cost, Product and Service [Extensible Enumeration] Product [Member]   Product [Member]   Product [Member] Product [Member]
Research and development expense $ 15,829   $ 14,856   $ 33,029 $ 30,231
Share-based compensation expense 8,209   6,949   16,625 14,791
Other segment expenses 26,779   20,934   53,133 39,254
Total operating expenses 93,884   87,954   190,964 166,762
Other income (expenses):            
Interest and other income, net 5,033   6,935   10,859 14,814
Interest expense (345)   (391)   (681) (773)
Income tax expense (5)   0   (13) (226)
Net Loss (68,327)   (66,122)   (141,660) (123,551)
Operating Segments | Product [Member]            
Revenues [Abstract]            
Total revenue 9,122   0   14,888 0
Operating Segments | Collaboration Revenue [Member]            
Revenues [Abstract]            
Total revenue 11,752   15,288   24,251 29,396
Operating Segments | Ziftomenib            
Revenues [Abstract]            
Research and development expense 34,938   37,584   71,818 67,531
Operating Segments | Darlifarnib [Member]            
Revenues [Abstract]            
Research and development expense 5,985   6,141   12,553 11,376
Operating Segments | Discovery Stage Program            
Revenues [Abstract]            
Research and development expense $ 1,901   $ 1,490   $ 3,301 $ 3,579